Evidence map›Paper›PMID 40650009›Full record

ArticleInternational journal of molecular sciences2025

Expression of

Liubov A Belik, Natella I Enukashvily, Natalia Y Semenova, Dmitrii I Ostromyshenskii, Ekaterina V Motyko, Anna N Kirienko, Daria V Kustova, Stanislav S Bessmeltsev, Sergey V Sidorkevich, Irina S Martynkevich

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Liubov A BelikLaboratory of the Non-Coding DNA Study, Institute of Cytology, Russian Academy of Sciences, 194064 St. Petersburg, Russia.ORCID 0000-0002-4589-8702
Natella I EnukashvilyLaboratory of the Non-Coding DNA Study, Institute of Cytology, Russian Academy of Sciences, 194064 St. Petersburg, Russia.ORCID 0000-0002-5971-7917
Natalia Y SemenovaRussian Research Institute of Hematology and Transfusiology, Federal Medical-Biological Agency of Russia of Russia, 1910243 St. Petersburg, Russia.ORCID 0000-0003-4069-0678
Dmitrii I OstromyshenskiiLaboratory of the Non-Coding DNA Study, Institute of Cytology, Russian Academy of Sciences, 194064 St. Petersburg, Russia.
Ekaterina V MotykoRussian Research Institute of Hematology and Transfusiology, Federal Medical-Biological Agency of Russia of Russia, 1910243 St. Petersburg, Russia.
Anna N KirienkoRussian Research Institute of Hematology and Transfusiology, Federal Medical-Biological Agency of Russia of Russia, 1910243 St. Petersburg, Russia.
Daria V KustovaRussian Research Institute of Hematology and Transfusiology, Federal Medical-Biological Agency of Russia of Russia, 1910243 St. Petersburg, Russia.
Stanislav S BessmeltsevRussian Research Institute of Hematology and Transfusiology, Federal Medical-Biological Agency of Russia of Russia, 1910243 St. Petersburg, Russia.
Sergey V SidorkevichRussian Research Institute of Hematology and Transfusiology, Federal Medical-Biological Agency of Russia of Russia, 1910243 St. Petersburg, Russia.
Irina S MartynkevichRussian Research Institute of Hematology and Transfusiology, Federal Medical-Biological Agency of Russia of Russia, 1910243 St. Petersburg, Russia.

Funding

The state assignment of Federal Medical-Biological Agency of the Russian Federation 123051000061-1
6 · The paper itself

Abstract

Mesenchymal stromal cells of the tumor microenvironment (TME) play a significant role in the progression of multiple myeloma (MM). The cells of the TME demonstrate resistance to treatment, thereby creating a favorable environment for disease relapse. The status of the TME during remission is poorly understood. An association between treatment response and TME status (including signaling pathways) has been suggested. One of the key players in the establishment of the MM TME is WNT signaling. In this study, we evaluated the expression of WNT family proteins in the TME and MM cells to assess their potential as TME markers and predictors of treatment response. A bioinformatic analysis of normal and malignant plasma cells, combined with an analysis of published data, revealed the following differentially expressed WNT genes:

Indexed as

Mesenchymal Stem CellsMultiple MyelomaWnt ProteinsAgedbeta CateninFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedProto-Oncogene ProteinsTumor MicroenvironmentWnt3A ProteinWnt-5a ProteinWnt Signaling Pathwaybeta CateninCTNNB1 protein, humanProto-Oncogene ProteinsWNT10B protein, humanWnt3A ProteinWnt-5a ProteinWNT5A protein, humanWnt Proteinsmesenchymal stromal cellsmultiple myelomatumor microenvironmentWNT10BWNT3AWNT5AWNT signaling pathwayβ-catenin

Identifiers

PMID40650009
PMCPMC12250531

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.